Leserbrief
Reconsidering Asparaginase in Leukemia Therapy
Acta Haematologica · 13.03.2026 · 1-3
DOI: 10.1159/000551486 ↗Kurz gefasst
Leserbrief in der Zeitschrift Acta Haematologica, online erschienen am 13.03.2026. Verfasst von Maria Frost und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
AsparaginaseChemotherapy eliminationImmunotherapyLeukemiaToxicity
Autor:innen und Institutionen
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mbgarcia@mdanderson.org.
Zitieren
APA
Frost, M., Subbiah, V., Cuglievan, B., & Garcia, M. B. (2026). Reconsidering Asparaginase in Leukemia Therapy. Acta Haematologica, 1-3. https://doi.org/10.1159/000551486
Vancouver
Frost M, Subbiah V, Cuglievan B, Garcia MB. Reconsidering Asparaginase in Leukemia Therapy. Acta Haematologica. 2026:1-3. doi:10.1159/000551486
BibTeX
@article{Frost2026,
author = {Frost, Maria and Subbiah, Vivek and Cuglievan, Branko and Garcia, Miriam B},
title = {Reconsidering Asparaginase in Leukemia Therapy},
journal = {Acta Haematologica},
year = {2026},
pages = {1--3},
doi = {10.1159/000551486}
}
EUVIMED